Cost-effectiveness of two screening strategies for Chlamydia trachomatis and Neisseria gonorrhoeae as part of the PrEP programme in the Netherlands: a modelling study
- 11 January 2021
- journal article
- research article
- Published by BMJ in Sexually Transmitted Infections
- Vol. 97 (8), 607-612
- https://doi.org/10.1136/sextrans-2020-054741
Abstract
Objectives Pre-exposure prophylaxis (PrEP) users are routinely tested four times a year (3 monthly) for asymptomatic Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) infections on three anatomical locations. Given the high costs of this testing to the PrEP programme, we assessed the impact of 3 monthly screening(current practice), compared with 6 monthly on the disease burden. We quantified the difference in impact of these two testing frequencies on the prevalence of CT and NG among all men who have sex with men (MSM) who are at risk of an STI, and explored the cost-effectiveness of 3-monthly screening compared with a baseline scenario of 6-monthly screening. Methods A dynamic infection model was developed to simulate the transmission of CT and NG among sexually active MSM (6500 MSM on PrEP and 29 531 MSM not on PrEP), and the impact of two different test frequencies over a 10-year period. The difference in number of averted infections was used to calculate incremental costs and quality-adjusted life-years (QALY) as well as an incremental cost-effectiveness ratio (ICER) from a societal perspective. Results Compared with 6-monthly screening, 3-monthly screening of PrEP users for CT and NG cost an additional €46.8 million over a period of 10 years. Both screening frequencies would significantly reduce the prevalence of CT and NG, but 3-monthly screening would avert and extra ~18 250 CT and NG infections compared with 6-monthly screening, resulting in a gain of ~81 QALYs. The corresponding ICER was ~€430 000 per QALY gained, which exceeded the cost-effectiveness threshold of €20 000 per QALY. Conclusions Three-monthly screening for CT and NG among MSM on PrEP is not cost-effective compared with 6-monthly screening. The ICER becomes more favourable when a smaller fraction of all MSM at risk for an STI are screened. Reducing the screening frequency could be considered when the PrEP programme is established and the prevalence of CT and NG decline.This publication has 13 references indexed in Scilit:
- Optimizing Strategies for Chlamydia trachomatis and Neisseria gonorrhoeae Screening in Men Who Have Sex With Men: A Modeling StudyClinical Infectious Diseases, 2020
- Preexposure Prophylaxis for the Prevention of HIV InfectionJAMA, 2019
- Risks of Antimicrobial Resistance in N. gonorrhoeae Associated with Intensive Screening Programs in Pre-Exposure Prophylaxis ProgramsClinical Infectious Diseases, 2018
- Incidence of Gonorrhea and Chlamydia Following Human Immunodeficiency Virus Preexposure Prophylaxis Among Men Who Have Sex With Men: A Modeling StudyClinical Infectious Diseases, 2017
- Effectiveness and safety of oral HIV preexposure prophylaxis for all populationsAIDS, 2016
- Duration of gonorrhoea and chlamydia infection at the pharynx and rectum among men who have sex with men: a systematic reviewSexual Health, 2016
- Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trialThe Lancet, 2015
- How robust are the natural history parameters used in chlamydia transmission dynamic models? A systematic reviewTheoretical Biology and Medical Modelling, 2014
- Prevalence of Rectal, Urethral, and Pharyngeal Chlamydia and Gonorrhea Detected in 2 Clinical Settings among Men Who Have Sex with Men: San Francisco, California, 2003Clinical Infectious Diseases, 2005
- Asymptomatic Gonorrhea in MenThe New England Journal of Medicine, 1974